Case Report
and kidneys. Bone scan revealed osseoarticular involvement, with focus in lumbar vertebra and the sacroiliac joint. He progressed to develop haemodynamic decompensation and acute respiratory distress syndrome. He was transferred to the intensive care unit and was initiated on mechanical ventilation and inotropic supports. He was initiated on intravenous meropenem 1 g Q8 h as a 3 h infusion and co-trimoxazole Q12 h. However, he continued to be bacteraemic 1 week after the initiation of intravenous antibiotic at the recommended doses. The meropenem trough level was assessed and was found to be 1.1 mcg/ml (therapeutic range -four times MIC for the organism). Hence, the doses of meropenem were escalated with a bolus of 2 g intravenously followed by 2 g every 8 th hourly as 3 h infusion, subsequent to which he improved clinically and achieved culture conversion in 48 h. His glycaemic status was optimised and was initiated on maintenance therapy with ceftazidime and trimethoprim-sulphamethoxazole. He improved clinically and was discharged.
disCussiOn
Management of melioidosis is challenging in view of the organism being intrinsically resistant to multiple antibacterial agents and the predilection to form deep-seated abscesses and osseous involvement. International Consensus Recommendations published in 2010 indicate ceftazidime as the drug of choice in acute phase among patients with no complications. [5] Among patients with neuromelioidosis and bacteraemic illness, meropenem is the standard of care. This is followed by oral eradication phase consisting of trimethoprim-sulphamethoxazole or amoxicillin-clavulanate.
Antimicrobial therapy using meropenem may not yield the desired response despite adhering to standardised dosing regimens in critically ill patients because of fluctuations in meropenem pharmacokinetics (PKs) during the course of management of the patient. This makes achievement of target concentrations of meropenem difficult due to variations in underlying pathophysiological conditions. [6] TDM is currently being used for antibiotic dose optimisation to improve attainment of PK/pharmacodynamic targets and outcomes of severe infections in the critically ill. [7] The changes in the volume of distribution (V d ) and drug clearance are the most common reasons for subtherapeutic dosing as well as dose-related toxicity. [8] In a study on the PKs of meropenem in critically ill patients, extended regimens of meropenem in combination with higher dosage were preferable for treating infections caused by bacteria with higher MICs. [9] Meropenem has time-dependent bactericidal property with the percentage of time; the drug concentrations are above MIC (%T>MIC) deciding the therapeutic response. [10, 11] In critically ill patients, keeping a target concentration of five times above MIC of the organism may improve the clinical outcome. [10] The MIC 50 and MIC 90 for B. pseudomallei isolate over 10-year period (n-203) reveal high susceptibility to carbapenems [ Table 1 ]. However, the conventional dosing regimen failed to attain the therapeutic range (five times above MIC), this could predispose to the development of antimicrobial resistance.
In our patient, TDM on standard drug dosing regimen had led to change in the dosing regimen and further to a favourable clinical as well as bacteriological response. The limitation in this particular case was the lack of continuous drug monitoring following dose escalation, rather clinical and microbiological response was used to guide therapy. Among patients with septicaemic melioidosis, use of high-dose meropenem (2 g 8 th hourly as 3 h infusion) in combination with TDM might yield better results.
COnCLusiOn
This case reiterates the importance of TDM of meropenem and the need for higher drug dosing in critically ill patients with septicaemic melioidosis, especially in those patients with deep-seated visceral abscesses, endovascular and osteoarticular involvement. 
